{
    "clinical_study": {
        "@rank": "62012", 
        "acronym": "CVH-CT02", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Platinum + Gemcitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV\n+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m\u00b2 given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
            }, 
            {
                "arm_group_label": "Arm B: Platinum+Gemcitabine+Trastuzumab", 
                "arm_group_type": "Experimental", 
                "description": "Trastuzumab: Charging dose = 8mg/kg on day 1; then 6mg/kg every 21 days given IV + Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV\n+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m\u00b2 given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "A multicenter, randomized, Phase 2 trial to study the effectiveness and feasibility of\n      association of trastuzumab with combination chemotherapy in advanced or metastatic bladder\n      cancer patients. Combining monoclonal antibody therapy with combination chemotherapy may\n      improve treatment efficacy on tumours overexpressed HER 2."
        }, 
        "brief_title": "Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma", 
        "condition": [
            "Recurrent Bladder Cancer", 
            "Stage IV Bladder Cancer", 
            "Transitional Cell Carcinoma of the Bladder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Transitional Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Transitional cell carcinoma of the urothelium or bladder histologically proven stage\n             IV AJCC [locally advanced (T4b and / or N + M0) unresectable or metastatic (M1)]\n\n          -  Tumor and / or metastasis overexpressing HER2 immunohistochemistry (IHC 3 +) or IHC 2\n             + and FISH +. Centralized analysis.\n\n          -  Measurable disease with at least one lesion with a diameter> 2 cm for conventional\n             methods (clinical examination, CT or MRI) or> 1 cm for the helical scanner. In case\n             of single metastasis, metastatic disease should be histologically proven\n\n          -  Age \u2265 18 years and \u226480 years\n\n          -  Life expectancy> 3 months,\n\n          -  Index performance status <2 according to ECOG PS,\n\n          -  No prior chemotherapy other than adjuvant and / or neoadjuvant chemotherapy, without\n             Herceptin \u00ae and complete for more than 6 months (naive to any previous chemotherapy\n             in the metastatic setting)\n\n          -  No radiotherapy within 4 weeks prior to inclusion,\n\n          -  Normal cardiac function as measured by ejection fraction (LVEF> 50%),\n\n          -  Blood and liver satisfactory constants:\n\n        Hematological criteria: - Neutrophils> 1.5 x 109 / L, - Chips> 100 x 109 / L - Hemoglobin>\n        10 g / dL, Liver function: - Alkaline phosphatase (unless bone metastases) <2 x N - Total\n        bilirubin <1.5 x N - transaminases (AST, ALT) <1.5 x N, renal Constants: - Creatinine\n        clearance > 30 ml / min (Cockcroft and Gault, cf. Annex XV protocol)\n\n        - Patient's written consent after full information.\n\n        Exclusion Criteria:\n\n          -  Concurrent treatment with an experimental drug, participation in another clinical\n             trial within <30 days\n\n          -  Patients previously treated with Herceptin \u00ae, or another treatment targeting growth\n             factors EGF (eg Iressa \u00ae, Tarceva \u00ae)\n\n          -  Existence of a severe pulmonary disease, liver or kidney is likely to be exacerbated\n             by the treatment,\n\n          -  Other medical conditions: congestive heart failure or angina pectoris even if\n             medically controlled failure, history of myocardial infarction before entering the\n             trial, hypertension or uncontrolled arrhythmias, significant valvular disease,\n\n          -  Patient with dyspnoea at rest or requiring oxygen therapy or with respiratory\n             failure,\n\n          -  Presence of a severe infection requiring antibiotics,\n\n          -  Presence of CNS metastases or meningeal\n\n          -  History of another malignancy uncured or cured for less than 5 years (except basal\n             cell carcinoma, papillary thyroid carcinoma in situ of the cervix treated)\n\n          -  Pregnant or lactating or not using effective contraception Women,\n\n          -  For Cisplatin only: carrying a serious neurological disease, current events devices>\n             NCI grade 2 neuropathy, hearing loss, creatinine clearance <60 ml / min, the patient\n             can not support a patient hydration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828736", 
            "org_study_id": "CVH-CT 02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm B: Platinum+Gemcitabine+Trastuzumab", 
                "description": "Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "anti-c-erB-2", 
                    "Herceptin", 
                    "MOAB HER2"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A: Platinum + Gemcitabine", 
                    "Arm B: Platinum+Gemcitabine+Trastuzumab"
                ], 
                "description": "Given IV, 1000 mg/m\u00b2 BSA on Day 1 and Day 8 every 21 days", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "dFdC", 
                    "difluorodeoxycytidine hydrochloride", 
                    "gemcitabine", 
                    "Gemzar", 
                    "gemcitabin hydrochloride"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A: Platinum + Gemcitabine", 
                    "Arm B: Platinum+Gemcitabine+Trastuzumab"
                ], 
                "description": "Given IV: AUC 5 on Day 1 every 21 days", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Carboplat", 
                    "CBDCA", 
                    "JM-8", 
                    "Paraplat", 
                    "Paraplatin"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A: Platinum + Gemcitabine", 
                    "Arm B: Platinum+Gemcitabine+Trastuzumab"
                ], 
                "description": "Given IV, 70 mg/m\u00b2 BSA on day 1 every 21 days", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "cis-Diamminedichloroplatinum(II)", 
                    "Platinum Diamminodichloride", 
                    "Diamminodichloride, Platinum", 
                    "cis-Platinum", 
                    "cis Platinum", 
                    "Dichlorodiammineplatinum", 
                    "cis-Diamminedichloroplatinum", 
                    "cis Diamminedichloroplatinum", 
                    "cis-Dichlorodiammineplatinum(II)", 
                    "Platinol", 
                    "Platidiam", 
                    "Platino", 
                    "NSC-119875", 
                    "Biocisplatinum"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Trastuzumab", 
                "Cisplatin", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Urothelial carcinoma", 
            "Trastuzumab", 
            "Treatment"
        ], 
        "lastchanged_date": "April 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Cliniques saint Luc - Universit\u00e9 Catholique de Louvain"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Besan\u00e7on", 
                        "country": "France", 
                        "zip": "25000"
                    }, 
                    "name": "CHU de Besan\u00e7on"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33000"
                    }, 
                    "name": "CHU H\u00f4pital Saint Andr\u00e9"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont Ferrand", 
                        "country": "France", 
                        "zip": "63000"
                    }, 
                    "name": "H\u00f4pital Jean Perrin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Roche-sur-yon", 
                        "country": "France", 
                        "zip": "85000"
                    }, 
                    "name": "Centre Hospitalier D\u00e9partemental de la Vend\u00e9e"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Mans", 
                        "country": "France", 
                        "zip": "72000"
                    }, 
                    "name": "Clinique Victor Hugo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13005"
                    }, 
                    "name": "CHU H\u00f4pital La Timone"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13009"
                    }, 
                    "name": "Institut Paoli Calmettes"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neuilly-Sur-Seine", 
                        "country": "France", 
                        "zip": "92200"
                    }, 
                    "name": "Clinique Hartmann"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75005"
                    }, 
                    "name": "Curie Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75014"
                    }, 
                    "name": "H\u00f4pital Cochin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75015"
                    }, 
                    "name": "H\u00f4pital Europ\u00e9en Georges Pompidou"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75010"
                    }, 
                    "name": "H\u00f4pital Saint Louis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75014"
                    }, 
                    "name": "Groupe Hospitalier Saint Joseph Paris"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suresnes", 
                        "country": "France", 
                        "zip": "92151"
                    }, 
                    "name": "H\u00f4pital Foch"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter Randomized Phase 2 Trial of Gemcitabine - Platinum With or Without Trastuzumab in Advanced or Metastatic Urothelial Carcinoma With HER2 Overexpression", 
        "overall_official": [
            {
                "affiliation": "H\u00f4pital Europ\u00e9en Georges Pompidou, Paris (France)", 
                "last_name": "St\u00e9phane Oudard, MD, PhD.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Curie Institute", 
                "last_name": "Philippe Beuzeboc, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: National Consultative Ethics Committee for Health and Life Sciences"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free survival", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed from radomization until progression or death, up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828736"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "Objective Response Rate will be assessed during treatment period, every 3 cycles, up to 7 months"
            }, 
            {
                "description": "Toxicity will be classify according to NCI-CTC criteria Version 2.0. Cardiac toxicity will be assessed according to the NYHA (New York Heart Association) criteria.", 
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed all along the study period, an expected average of 3 years"
            }, 
            {
                "description": "Quality of Life will be assessed according to the EORTC QLQ-C30 Version 3 questionnaire", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Quality of Life will be assessed during the study period, every 3 cycles (Arm A patients) or every 3 months (Arm B patients), up to 3 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed from randomization until death or lost of follow-up, up to 3 years"
            }
        ], 
        "source": "Association Pour La Recherche des Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Association Pour La Recherche des Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2004", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}